Partner Headlines - GSK

  1. Markets Little Changed Ahead Of The Federal Reserve's Policy ...

    Benzinga
  2. GlaxoSmithKline

    IBD
  3. Stock Futures Up, But Wobbly; Boeing, Apple, Biogen Rising

    IBD
  4. Mylan Wins Motion To Enjoin GlaxoSmithKline From Providing Paroxetine ...

    Benzinga
  5. Morning Market Movers

    Benzinga
  6. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With ...

    Benzinga
  7. Highest Yielding Stocks Widely Held By The Gurus

    GuruFocus
  8. British Stocks: Sweet Spot For European Value

    YCharts
  9. Diamond Hill Capital Comments on GlaxoSmithKline PLC

    GuruFocus
  10. ISIS Pharma Trades Up Premarket; NYT Says Has Potential Heart ...

    Benzinga
  11. Advances In HIV, Hep C Treatments Could Spark Renewed Interest ...

    Benzinga
  12. InterMune Up On Bullish View Of U.S. Esbriet Launch

    IBD
  13. UPDATE: Glaxo, Theravance Report Positive Data from Two Studies ...

    Benzinga
  14. Major British Companies Lead Top Guru-Held UK and Ireland Stocks ...

    GuruFocus
  15. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  16. ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica ...

    Benzinga
  17. Aura Of Light Shines On Pernix Shares Following Treximet Acquisition

    Benzinga
  18. Cross-Border Megamergers Drive Global Takeover Boom

    IBD
  19. Google Celebrates Dorothy Hodgkin & Her Contributions To Chemistry

    Benzinga
  20. Can Pfizer Make Up Its Loss?

    GuruFocus
  21. Merck Sells Consumer Unit To Bayer To Focus On R&D

    IBD
  22. Bayer Buys Merck Consumer Care Unit

    FoxBusiness
  23. AstraZeneca Rejects Pfizer's $106B Buyout Bid

    FoxBusiness
  24. #PreMarket Primer: Thursday, May 1: Fed Brushes Off Dissapointing ...

    Benzinga
  25. Glaxo hurt by Advair scandal

    IBD
  26. Nasdaq Leads Early Stock Slide; Twitter Tumbles, Trinity Rises

    IBD
  27. Stock Futures Slip as Traders Brace for Economic Flood

    FoxBusiness
  28. Disappointing GDP Reading Weighs on Stocks

    FoxBusiness
  29. China Rule Change Further Opens Yuan To World Markets

    IBD
  30. Weekly 52-Week Highs Highlight: AV, XEL, OKE, GSK

    GuruFocus
  31. GSK, MMV Announce Commencement of Phase III Programme of Tafenoquine ...

    Benzinga
  32. These Three Pharmaceutical Companies Shake The Market With Their ...

    GuruFocus
  33. Benzinga Weekly Preview: Earnings Season Continues As Biotech ...

    Benzinga
  34. Big Pharmas Swap Specialties

    IBD
  35. Drugmakers Prod European Stocks To Post-Easter Rally

    IBD
  36. Valeant's Bid For Allergan Boosts Ethical Drug Stocks

    IBD
  37. Novartis, Glaxo Swap Units; Valeant Bids For Allergan

    IBD
  38. Stocks Rise In Higher Volume; Gilead Up After Hours

    IBD
  39. S&P 500, Nasdaq Rise For Sixth Day As Volume Picks Up

    IBD
  40. Pharma Deal Frenzy: A Bid to Boost Profits, Cut Risk

    FoxBusiness
  41. Amgen Slumps After 1Q Earnings Miss

    FoxBusiness
  42. Drug ETFs Surge On M&A Activity (AGN, VRX, IHE, XPH, PPH, AZN)

    Benzinga
  43. Novartis, Glaxo Swap Units; Lilly Buying Animal Biz

    IBD
  44. Stock Futures Mixed And Busy; Allergan, Netflix, Glaxo Climb

    IBD
  45. Novartis Announces Multi-Billion-Dollar Revamp

    FoxBusiness
  46. US Stock Futures Edge Higher Ahead Of McDonald's Earnings

    Benzinga
  47. Stock Futures Steady Amid Raft of Health M&A

    FoxBusiness
  48. Wall Street Ticks Up as Traders Parse News Deluge

    FoxBusiness
  49. GlaxoSmithKline Finally Received Approval from FDA for Its Diabetes ...

    GuruFocus
  50. Has A Streamlined FDA Raised The Value Of Drug Stocks?

    IBD
  51. Pharmaceutical Stocks For Income, Value, And Growth Investors

    Benzinga
  52. New Glaxo bribery inquiries

    IBD
  53. Race for Vaccines, Treatments as West Africa Ebola Death Toll ...

    Benzinga
  54. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With ...

    Benzinga
  55. GlaxoSmithKline

    IBD
  56. Amgen, GSK End Marketing Pact for Osteoporosis Drug

    FoxBusiness
  57. Biotech Auxilium Boosts Position In Men's Health Care

    IBD
  58. Glaxosmithkline Confirms Warning Letter Received from FDA o March ...

    Benzinga
  59. GSK buys up Indonesia unit

    IBD
  60. GSK Recalls Alli in U.S. After Package Tampering

    FoxBusiness
  61. GSK, FDA Probe Tampering of Weight-Loss Drug Alli

    FoxBusiness
  62. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  63. Market Wrap For March 20: Investors Showing No Post-Fed Decision ...

    Benzinga
  64. Glaxo Cancer Vaccine Fails, Testing Continues

    FoxBusiness
  65. Morning Market Losers

    Benzinga
  66. US Stock Futures Drop Ahead Of Jobless Claims Report

    Benzinga
  67. Agenus Therapeutics Reports GlaxoSmithKline's Magrit Study Does ...

    Benzinga
  68. T. Rowe Price's Brian Rogers Joins GuruFocus for Q&A - Ask an ...

    GuruFocus
  69. T. Rowe Price CIO Brian Rogers Joins GuruFocus for Q&A - Ask ...

    GuruFocus
  70. Gilead's HCV Challengers Near The Starting Gate

    IBD
  71. Brian Rogers of T. Rowe Price Joins GuruFocus for Q&A - Ask a ...

    GuruFocus
  72. Gilead's HCV Challengers Near The Starting Gate

    IBD
  73. Prosensa Muscular Dystrophy Data Send Stock Rising

    IBD
  74. A HIV shot could replace pills

    IBD
  75. Why Long-Term Investor Warren Buffett's Company Just Sold 2 Stocks

    GuruFocus
  76. GlaxoSmithKline, Kinder Morgan And Others Insiders Have Been ...

    Benzinga
  77. Glaxo's COPD Drug Gets European Green Light

    FoxBusiness
  78. Berkshire Hathaway Files SEC 13F

    Benzinga
  79. Pharmacyclics' Imbruvica Wins Second Cancer Approval

    IBD
  80. Novartis' 'Cliffy' Business

    GuruFocus
  81. Glaxo expects to retain lead

    IBD
  82. Benzinga Weekly Preview: Twitter To Release Earnings For The ...

    Benzinga
  83. Ariad Shares Continue to Surge Amidst Buyout Rumors

    Benzinga
  84. Tweedy Browne Global Value Fund New Buy and Adds

    GuruFocus
  85. Pharmacyclics: Facts Behind $10B Market Cap

    YCharts
  86. $10B Market By 2022: Pharmacyclic’s Piece Of It

    YCharts
  87. Bristol-Myers: Don't Let This One Get Away

    GuruFocus
  88. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think ...

    GuruFocus
  89. Morning Market Losers

    Benzinga
  90. Benzinga's Top #PreMarket Losers

    Benzinga
  91. Pharmacyclics, Valeant, Celgene Up On Bullish News

    IBD
  92. PharmacyclicsDrug Trial To End Early On Strong Data

    IBD
  93. Stock Futures Positive, Steady; Netflix Dives On Downgrade

    IBD
  94. New Drugs Could Change Cancer Landscape In 2014

    IBD
  95. ObamaCare = Drug Maker Assistance Act

    YCharts
  96. Why MasterCard, Up 64% in 2013, Isn’t Done

    YCharts
  97. Merck’s Bad-Mouthing Of Generic: $21 Million Fine

    YCharts
  98. Prosensa Comments on Drisapersen Program Update

    Benzinga
  99. Merck Collaborates with GlaxoSmithKline on MK-3475

    Benzinga
  100. Glaxo Curbs Drug Promotion

    IBD
Trading Center